Compare MBIN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | XNCR |
|---|---|---|
| Founded | 1990 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2017 | 2013 |
| Metric | MBIN | XNCR |
|---|---|---|
| Price | $49.51 | $33.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $67.00 | $43.83 |
| AVG Volume (30 Days) | 115.6K | ★ 1.5M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 4.79 | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $10.52 | $58.19 |
| Revenue Next Year | $3.15 | N/A |
| P/E Ratio | $10.44 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $30.95 | $10.38 |
| 52 Week High | $56.87 | $40.60 |
| Indicator | MBIN | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 54.03 |
| Support Level | $47.81 | $22.80 |
| Resistance Level | $51.01 | $33.60 |
| Average True Range (ATR) | 1.40 | 2.08 |
| MACD | -0.36 | -0.54 |
| Stochastic Oscillator | 3.97 | 35.21 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.